FDA meets with Guidant to discuss heart device defect

05/25/2005 | NYTimes.com

The Food and Drug Administration yesterday met with Guidant to discuss the company's disclosure this week that it failed to disclose a design flaw in an implantable defibrillator and did not reveal that the manufacturing process was changed in 2002 to fix it. Company officials said they followed FDA guidelines in reporting problems about the device to the agency.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC